Lundbeck CEO joins board of directors at Syros Pharmaceuticals

Deborah Dunsire, CEO at Lundbeck, has been appointed to the board of directors at Syros Pharmaceuticals.

Photo: Gregers Tycho/Ritzau/Ritzau Scanpix

A fresh face has joined the board at the US-based biopharmaceutical company Syros Pharmaceuticals in the form of Deborah Dunsire, CEO at Lundbeck, a press release reveals.

"Syros has all the elements for building an enduring company – programs with the potential to set new standards of care for patients, a discovery engine to continue to fuel its pipeline, and great people," Dunsire says in the release, and adds:

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP recommends nine new drugs, rejects one

Roche and Biogen are among the companies that have received recommendation for approval from the European Medicines Agency's committee (CHMP) at its September meeting. One Pfizer drug was the sole candidate to be rejected.

CEO at WSA: No clarity on EQT exit plans yet

The time horizon for the venture fund EQT's investment in WS Audiology should be ending soon, but according to Group CEO Eric Bernard, there is no clarity on when the potential changes might occur.

Further reading

Related articles

Trial banner

Latest news

See all jobs